全球阿茲海默症治療市場，依藥物類別（膽鹼能藥物、美金剛、複方藥物、乙醯膽鹼酯酶 (AChE)抑制劑和免疫球蛋白）、分銷管道（醫院藥房、零售藥房和線上銷售）、國家/地區（美國、加拿大、墨西哥、秘魯、巴西、阿根廷、南美洲其他地區、德國、義大利、英國、法國、西班牙、荷蘭、比利時、瑞士、土耳其、俄羅斯、匈牙利、立陶宛、奧地利、愛爾蘭、挪威、波蘭、歐洲其他地區、日本、中國、印度、韓國、澳洲、新加坡、馬來西亞、泰國、印尼、菲律賓、越南、亞太其他地區、南非、沙烏地阿拉伯、阿聯酋、科威特、以色列、埃及、中東和非洲其他地區）劃分，產業趨勢及至2029 年的預測。
阿茲海默症治療市場分析與洞察
Data Bridge Market Research 分析顯示，2022-2029 年預測期內，阿茲海默症治療市場將以約 8.79% 的複合年增長率成長。對標靶治療模式的需求不斷增長、新藥和療法研發活動的激增、阿茲海默症病例在人群中的增加以及醫療保健基礎設施建設支出的增加，是推動阿茲海默症治療市場成長的主要因素。
阿茲海默症是一種導致腦部神經細胞退化的疾病。它是老年人群中最常見的癡呆症病因。阿茲海默症會導致患者認知功能喪失，例如記憶力、語言能力和行為能力下降。
監管機構日益增多的特殊認定是推動市場成長的主要因素。醫療基礎建設投入的增加、發展中地區公眾對疾病認知的提高、政府加大力度在落後地區推廣疾病防治意識，以及市場參與者之間戰略合作的日益頻繁，也是促進市場增長的其他因素。此外，對個人化藥物和價格合理的診斷測試的需求激增，也將創造豐厚的市場成長機會。
然而，發展中國家和欠發達經濟體缺乏技術嫻熟的醫療專業人員以及不利的報銷機制，將對市場成長構成重大挑戰。此外，研發成本高昂、治療費用不斷上漲、部分藥物尚未獲得相關機構批准以及欠發達經濟體醫療設施落後，都將進一步阻礙市場成長。
這份阿茲海默症治療市場報告詳細介紹了近期新進展、貿易法規、進出口分析、生產分析、價值鏈優化、市場份額、國內外市場參與者的影響、新興收入來源的機遇分析、市場法規變化、戰略市場增長分析、市場規模、各細分市場增長、應用領域及主導地位、產品審批、產品發布、地域擴張以及市場技術創新。如需了解更多關於阿茲海默症治療市場的信息，請聯繫Data Bridge Market Research索取分析師簡報，我們的團隊將協助您做出明智的市場決策，實現市場成長。
全球阿茲海默症治療市場範圍和市場規模
阿茲海默症治療市場按藥物類別和分銷管道進行細分。這些細分市場的成長將有助於您分析行業中成長緩慢的細分市場，並為用戶提供有價值的市場概覽和市場洞察，以幫助他們制定策略決策，從而確定核心市場應用。
- 根據藥物類別，阿茲海默症治療市場可分為膽鹼能藥物、美金剛、複方藥物、乙醯膽鹼酯酶 (AChE) 抑制劑和免疫球蛋白。
- 根據分銷管道，阿茲海默症治療市場可分為醫院藥房、零售藥房和線上銷售。
阿茲海默症治療市場國家層面分析
如上所述，本文分析了阿茲海默症治療市場，並按國家、藥物類別和分銷管道提供了市場規模洞察和趨勢。
阿茲海默症治療市場報告涵蓋的國家包括：北美洲的美國、加拿大和墨西哥；南美洲的秘魯、巴西、阿根廷和南美洲其他國家；歐洲的德國、義大利、英國、法國、西班牙、荷蘭、比利時、瑞士、土耳其、俄羅斯、匈牙利、立陶宛、奧地利、愛爾蘭、挪威、波蘭和歐洲其他國家；亞太地區的日本、中國、印度、韓國、澳洲、新加坡、馬來西亞、泰國、印尼、菲律賓、越南和亞太地區的其他國家；以及中東和非洲地區的南非、沙烏地阿拉伯、阿聯酋、科威特、以色列、埃及和中東和非洲其他國家。
北美地區在阿茲海默症治療市場佔據主導地位，這主要歸功於其最早採用創新技術、不斷增長的研發能力、對慢性病治療和管理意識的提高以及完善的監管框架。預計亞太地區在預測期內將取得顯著成長，並實現最高的複合年增長率。這主要得益於醫療基礎設施建設投入的增加、老年人口基數的持續增長、人們對阿茲海默症認識的提高以及研發活動的增加。
阿茲海默症治療市場報告的國別部分還提供了影響各個市場的因素以及國內市場監管變化，這些因素和變化會影響市場的當前和未來趨勢。消費量、生產地點和產量、進出口分析、價格趨勢分析、原材料成本、下游和上游價值鏈分析等數據點是預測各國市場前景的主要指標。此外，在進行國別數據預測分析時，還會考慮全球品牌的市場佔有率和可用性，以及它們因本地品牌競爭激烈或稀缺而面臨的挑戰，以及國內關稅和貿易路線的影響。
患者流行病學分析
阿茲海默症治療市場報告也提供詳細的市場分析，涵蓋患者分析、預後和治療方案。報告中提供的數據變數包括盛行率、發病率、死亡率和依從率等。報告分析了流行病學對阿茲海默症治療市場成長的直接或間接影響，旨在建立更穩健的隊列多元統計模型，從而預測阿茲海默症治療市場在增長期內的發展趨勢。
競爭格局及阿茲海默症治療市場佔有率分析
阿茲海默症治療市場競爭格局分析報告按競爭對手提供了詳細信息，包括公司概況、財務狀況、收入、市場潛力、研發投入、新市場拓展計劃、全球佈局、生產基地及設施、產能、公司優勢與劣勢、產品發布、產品線寬度與廣度以及應用領域優勢。以上數據僅與各公司在阿茲海默症治療市場的業務相關。
阿茲海默症治療市場的主要參與者包括：艾爾建、衛材株式會社、諾華公司、第一三共株式會社、默茲製藥、輝瑞公司、強生服務公司、靈北製藥、百健、阿斯特捷利康、羅氏公司、VTV Therapeutics、TauRx、禮來公司、梯瓦工業有限公司、小型梯瓦工業有限公司、小梯瓦工業有限公司、AB. Science、艾伯維公司、百時美施貴寶公司、武田藥品工業株式會社、魯賓、庫克、葛蘭素史克公司、新基公司和拜耳公司等。
可提供客製化服務：全球阿茲海默症治療市場
Data Bridge Market Research是一家領先的高級市場調查公司。我們致力於為新舊客戶提供符合其目標的數據和分析服務。本報告可根據您的需求進行定制，包括目標品牌的價格趨勢分析、其他國家/地區的市場分析（請索取國家/地區列表）、臨床試驗結果數據、文獻綜述、翻新市場和產品基礎分析。我們可以對目標競爭對手進行市場分析，涵蓋從技術分析到市場組合策略的各個面向。我們可以根據您的要求，以您所需的資料格式和樣式，新增您所需的任意數量的競爭對手資料。我們的分析師團隊還可以為您提供原始的 Excel 資料透視表（概況手冊），或協助您根據報告中的資料集建立簡報。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL ALZHEIMER’S DISEASE TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL ALZHEIMER’S DISEASE TREATMENT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY MODELING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL ALZHEIMER’S DISEASE TREATMENT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMSUM INSIGHTS
4.1 PORTER'S 5 FORCES
4.2 PESTEL ANALYSIS
5 EPIDEMIOLOGY
5.1 INCIDENCE OF ALL BY GENDER
5.2 TREATMENT RATE
5.3 MORTALITY RATE
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
5.5 PATEINT TREATMENT SUCCESS RATES
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH NEUROLOGIST
6.8 INTERVIEWS WITH GENETICS SPECIALIST
6.9 OTHER KOL SNAPSHOTS
7 REGULATORY SCENARIO
7.1 FDA APPROVALS
7.2 EMA APPROVALS
8 MERGERS AND ACQUISITION
8.1 LICENSING
8.2 COMMERCIALIZATION AGREEMENTS
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.3.1 AGB101
9.3.2 BDPO-1603
9.3.3 GANETENERUMAB
9.3.4 GV-871
9.3.5 LECANEMAB
9.3.6 OTHERS
9.4 PHASE II CANDIDATES
9.4.1 ATUZAGINISTAT
9.4.2 AZELIRAGON
9.4.3 BLARCAMESINE
9.4.4 BREXIPRAZOLE
9.4.5 NABILONE
9.4.6 OTHERS
9.5 PHASE I CANDIDATES
9.5.1 AVP-786
9.5.2 OTHERS
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
10 MARKET OVERVIEW
10.1 DRIVERS
10.2 RESTRAINS
10.3 OPPURTUNITY
10.4 CHALLENGES
11 GLOBAL ALZHEIMER’S DISEASE TREATMENT MARKET, BY TREATMENT
11.1 OVERVIEW
11.2 MEDICATION
11.2.1 CHOLINESTERASE INHIBITORS
11.2.1.1. BY DRUGS
11.2.1.1.1. DONEPEZIL
11.2.1.1.1.1 MARKET VALUE (USD MN)
11.2.1.1.1.2 MARKET VOLUME (SU)
11.2.1.1.1.3 AVERAGE SELLING PRICE (USD)
11.2.1.1.2. RIVASTIGMINE
11.2.1.1.2.1 MARKET VALUE (USD MN)
11.2.1.1.2.2 MARKET VOLUME (SU)
11.2.1.1.2.3 AVERAGE SELLING PRICE (USD)
11.2.1.1.3. GALANTAMINE
11.2.1.1.3.1 MARKET VALUE (USD MN)
11.2.1.1.3.2 MARKET VOLUME (SU)
11.2.1.1.3.3 AVERAGE SELLING PRICE (USD)
11.2.1.1.4. OTHERS
11.2.1.2. BY DRUG TYPE
11.2.1.2.1. GENERICS
11.2.1.2.2. BRANDED
11.2.1.2.2.1 ARICEPT
11.2.1.2.2.1.1. MARKET VALUE (USD MN)
11.2.1.2.2.1.2. MARKET VOLUME (SU)
11.2.1.2.2.1.3. AVERAGE SELLING PRICE (USD)
11.2.1.2.2.2 EXELON
11.2.1.2.2.2.1. MARKET VALUE (USD MN)
11.2.1.2.2.2.2. MARKET VOLUME (SU)
11.2.1.2.2.2.3. AVERAGE SELLING PRICE (USD)
11.2.1.2.2.3 RAZADYNE
11.2.1.2.2.3.1. MARKET VALUE (USD MN)
11.2.1.2.2.3.2. MARKET VOLUME (SU)
11.2.1.2.2.3.3. AVERAGE SELLING PRICE (USD)
11.2.1.2.2.4 OTHERS
11.2.2 NMDA ANTAGONIST (MEMANTINE)
11.2.2.1.1. MARKET VALUE (USD MN)
11.2.2.1.2. MARKET VOLUME (SU)
11.2.2.1.3. AVERAGE SELLING PRICE (USD)
11.2.3 ADUCANUMAB
11.2.3.1.1. MARKET VALUE (USD MN)
11.2.3.1.2. MARKET VOLUME (SU)
11.2.3.1.3. AVERAGE SELLING PRICE (USD)
11.2.4 ANXIOLYTICS
11.2.4.1. BY DRUGS
11.2.4.1.1. LORAZEPAM
11.2.4.1.1.1 MARKET VALUE (USD MN)
11.2.4.1.1.2 MARKET VOLUME (SU)
11.2.4.1.1.3 AVERAGE SELLING PRICE (USD)
11.2.4.1.2. OXAZEPAM
11.2.4.1.2.1 MARKET VALUE (USD MN)
11.2.4.1.2.2 MARKET VOLUME (SU)
11.2.4.1.2.3 AVERAGE SELLING PRICE (USD)
11.2.4.1.3. OTHERS
11.2.4.2. BY DRUG TYPE
11.2.4.2.1. GENERICS
11.2.4.2.2. BRANDED
11.2.4.2.2.1 TRAPEX
11.2.4.2.2.1.1. MARKET VALUE (USD MN)
11.2.4.2.2.1.2. MARKET VOLUME (SU)
11.2.4.2.2.1.3. AVERAGE SELLING PRICE (USD)
11.2.4.2.2.2 SERAX
11.2.4.2.2.2.1. MARKET VALUE (USD MN)
11.2.4.2.2.2.2. MARKET VOLUME (SU)
11.2.4.2.2.2.3. AVERAGE SELLING PRICE (USD)
11.2.4.2.2.3 OTHERS
11.2.5 ANTIDEPRESSANT
11.2.5.1. BY DRUGS
11.2.5.1.1. CITALOPRAM
11.2.5.1.1.1 MARKET VALUE (USD MN)
11.2.5.1.1.2 MARKET VOLUME (SU)
11.2.5.1.1.3 AVERAGE SELLING PRICE (USD)
11.2.5.1.2. PAROXETINE
11.2.5.1.2.1 MARKET VALUE (USD MN)
11.2.5.1.2.2 MARKET VOLUME (SU)
11.2.5.1.2.3 AVERAGE SELLING PRICE (USD)
11.2.5.1.3. ESCITALOPRAM
11.2.5.1.3.1 MARKET VALUE (USD MN)
11.2.5.1.3.2 MARKET VOLUME (SU)
11.2.5.1.3.3 AVERAGE SELLING PRICE (USD)
11.2.5.1.4. MIRTAZAPINE
11.2.5.1.4.1 MARKET VALUE (USD MN)
11.2.5.1.4.2 MARKET VOLUME (SU)
11.2.5.1.4.3 AVERAGE SELLING PRICE (USD)
11.2.5.1.5. TRAZODONE
11.2.5.1.5.1 MARKET VALUE (USD MN)
11.2.5.1.5.2 MARKET VOLUME (SU)
11.2.5.1.5.3 AVERAGE SELLING PRICE (USD)
11.2.5.1.6. OTHERS
11.2.5.2. BY DRUG TYPE
11.2.5.2.1. GENERICS
11.2.5.2.2. BRANDED
11.2.5.2.2.1 AKARIN
11.2.5.2.2.1.1. MARKET VALUE (USD MN)
11.2.5.2.2.1.2. MARKET VOLUME (SU)
11.2.5.2.2.1.3. AVERAGE SELLING PRICE (USD)
11.2.5.2.2.2 PAXIL
11.2.5.2.2.2.1. MARKET VALUE (USD MN)
11.2.5.2.2.2.2. MARKET VOLUME (SU)
11.2.5.2.2.2.3. AVERAGE SELLING PRICE (USD)
11.2.5.2.2.3 LEXAPRO
11.2.5.2.2.3.1. MARKET VALUE (USD MN)
11.2.5.2.2.3.2. MARKET VOLUME (SU)
11.2.5.2.2.3.3. AVERAGE SELLING PRICE (USD)
11.2.5.2.2.4 REMERON
11.2.5.2.2.4.1. MARKET VALUE (USD MN)
11.2.5.2.2.4.2. MARKET VOLUME (SU)
11.2.5.2.2.4.3. AVERAGE SELLING PRICE (USD)
11.2.5.2.2.5 DESYREL
11.2.5.2.2.5.1. MARKET VALUE (USD MN)
11.2.5.2.2.5.2. MARKET VOLUME (SU)
11.2.5.2.2.5.3. AVERAGE SELLING PRICE (USD)
11.2.5.2.2.6 OTHERS
11.2.5.3. BY DRUG TYPE
11.2.5.3.1. GENERICS
11.2.5.3.2. BRANDED
11.2.5.3.2.1 CELEXA
11.2.5.3.2.1.1. MARKET VALUE (USD MN)
11.2.5.3.2.1.2. MARKET VOLUME (SU)
11.2.5.3.2.1.3. AVERAGE SELLING PRICE (USD)
11.2.5.3.2.2 AROPAX
11.2.5.3.2.2.1. MARKET VALUE (USD MN)
11.2.5.3.2.2.2. MARKET VOLUME (SU)
11.2.5.3.2.2.3. AVERAGE SELLING PRICE (USD)
11.2.5.3.2.3 LEXAPRO
11.2.5.3.2.3.1. MARKET VALUE (USD MN)
11.2.5.3.2.3.2. MARKET VOLUME (SU)
11.2.5.3.2.3.3. AVERAGE SELLING PRICE (USD)
11.2.5.3.2.4 MIRATAZ
11.2.5.3.2.4.1. MARKET VALUE (USD MN)
11.2.5.3.2.4.2. MARKET VOLUME (SU)
11.2.5.3.2.4.3. AVERAGE SELLING PRICE (USD)
11.2.5.3.2.5 OTHERS
11.2.6 ANTIPSYCHOTIC MEDICINES
11.2.6.1. BY DRUGS
11.2.6.1.1. ARIPIPRAZOLE
11.2.6.1.1.1 MARKET VALUE (USD MN)
11.2.6.1.1.2 MARKET VOLUME (SU)
11.2.6.1.1.3 AVERAGE SELLING PRICE (USD)
11.2.6.1.2. HALOPERIDOL
11.2.6.1.2.1 MARKET VALUE (USD MN)
11.2.6.1.2.2 MARKET VOLUME (SU)
11.2.6.1.2.3 AVERAGE SELLING PRICE (USD)
11.2.6.1.3. OLANZAPINE
11.2.6.1.3.1 MARKET VALUE (USD MN)
11.2.6.1.3.2 MARKET VOLUME (SU)
11.2.6.1.3.3 AVERAGE SELLING PRICE (USD)
11.2.6.1.4. RISPERIDONE
11.2.6.1.4.1 MARKET VALUE (USD MN)
11.2.6.1.4.2 MARKET VOLUME (SU)
11.2.6.1.4.3 AVERAGE SELLING PRICE (USD)
11.2.6.1.5. OTHERS
11.2.6.2. BY DRUG TYPE
11.2.6.2.1. GENERICS
11.2.6.2.2. BRANDED
11.2.6.2.2.1 ABILIFY
11.2.6.2.2.1.1. MARKET VALUE (USD MN)
11.2.6.2.2.1.2. MARKET VOLUME (SU)
11.2.6.2.2.1.3. AVERAGE SELLING PRICE (USD)
11.2.6.2.2.2 HALODOL
11.2.6.2.2.2.1. MARKET VALUE (USD MN)
11.2.6.2.2.2.2. MARKET VOLUME (SU)
11.2.6.2.2.2.3. AVERAGE SELLING PRICE (USD)
11.2.6.2.2.3 ZYPREXA
11.2.6.2.2.3.1. MARKET VALUE (USD MN)
11.2.6.2.2.3.2. MARKET VOLUME (SU)
11.2.6.2.2.3.3. AVERAGE SELLING PRICE (USD)
11.2.6.2.2.4 RISPERDAL
11.2.6.2.2.4.1. MARKET VALUE (USD MN)
11.2.6.2.2.4.2. MARKET VOLUME (SU)
11.2.6.2.2.4.3. AVERAGE SELLING PRICE (USD)
11.2.6.2.2.5 OTHERS
11.2.7 OTHERS
11.3 THERAPY
11.3.1 COGNITIVE STIMULATION THERAPY (CST)
11.3.2 COGNITIVE REHABILITATION
11.3.3 OTHERS
12 GLOBAL ALZHEIMER’S DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 ORAL
12.2.1 SOLID ORAL DRUGS
12.2.1.1. TABLETS
12.2.1.2. CAPSULES
12.2.1.3. POWDERS
12.2.1.4. PILLS
12.2.1.5. OTHERS
12.2.2 LIQUID ORAL DRUGS
12.2.2.1. SYRUPS
12.2.2.2. SOLUTIONS
12.2.2.3. OTHERS
12.2.3 SEMI-SOLID ORAL DRUGS
12.2.3.1. GELS
12.2.3.2. EMULSIONS
12.2.3.3. ELIXIRS
12.2.3.4. OTHERS
12.3 TOPICAL
12.4 PARENTERAL
12.4.1 INTRAVENOUS
12.4.2 SUBCUTANEOUS
12.4.3 OTHERS
13 GLOBAL ALZHEIMER’S DISEASE TREATMENT MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 SPECIALTY CLINICS
13.4 HOME HEALTHCARE
13.5 OTHERS
14 GLOBAL ALZHEIMER’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 RETAIL PHARMACY
14.4 ONLINE PHARMACY
14.5 OTHERS
15 GLOBAL ALZHEIMER’S DISEASE TREATMENT MARKET, BY GEOGRAPHY
15.1 GLOBAL ALZHEIMER’S DISEASE TREATMENT MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
15.2 NORTH AMERICA
15.2.1 U.S.
15.2.1.1. U.S. ALZHEIMER’S DISEASE TREATMENT MARKET, BY TYPE
15.2.1.2. U.S. ALZHEIMER’S DISEASE TREATMENT MARKET, BY APPLICATION
15.2.1.3. U.S. ALZHEIMER’S DISEASE TREATMENT MARKET, BY SOURCE
15.2.1.4. U.S. ALZHEIMER’S DISEASE TREATMENT MARKET, BY END USER
15.2.2 CANADA
15.2.3 MEXICO
15.2.4 DOMINICAN REPUBLIC
15.2.5 JAMAICA
15.2.6 PANAMA
15.3 EUROPE
15.3.1 GERMANY
15.3.2 FRANCE
15.3.3 U.K.
15.3.4 HUNGARY
15.3.5 LITHUANIA
15.3.6 AUSTRIA
15.3.7 IRELAND
15.3.8 NORWAY
15.3.9 POLAND
15.3.10 ITALY
15.3.11 SPAIN
15.3.12 RUSSIA
15.3.13 TURKEY
15.3.14 NETHERLANDS
15.3.15 SWITZERLAND
15.3.16 REST OF EUROPE
15.4 ASIA-PACIFIC
15.4.1 JAPAN
15.4.2 CHINA
15.4.3 TAIWAN
15.4.4 SOUTH KOREA
15.4.5 INDIA
15.4.6 AUSTRALIA
15.4.7 SINGAPORE
15.4.8 THAILAND
15.4.9 MALAYSIA
15.4.10 INDONESIA
15.4.11 PHILIPPINES
15.4.12 VIETNAM
15.4.13 REST OF ASIA-PACIFIC
15.5 SOUTH AMERICA
15.5.1 BRAZIL
15.5.2 ECUADOR
15.5.3 CHILE
15.5.4 COLOMBIA
15.5.5 VENEZUELA
15.5.6 ARGENTINA
15.5.7 PERU
15.5.8 CURAÇAO
15.5.9 PARAGUAY
15.5.10 URUGUAY
15.5.11 TRINIDAD AND TOBAGO
15.5.12 REST OF SOUTH AMERICA
15.6 MIDDLE EAST AND AFRICA
15.6.1 SOUTH AFRICA
15.6.2 SAUDI ARABIA
15.6.3 UAE
15.6.4 EGYPT
15.6.5 KUWAIT
15.6.6 ISRAEL
15.6.7 BOLIVIA
15.6.8 REST OF MIDDLE EAST AND AFRICA
15.7 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
16 GLOBAL ALZHEIMER’S DISEASE TREATMENT MARKET, SWOT AND DBMR ANALYSIS
17 GLOBAL ALZHEIMER’S DISEASE TREATMENT MARKET, COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17.5 MERGERS & ACQUISITIONS
17.6 NEW PRODUCT DEVELOPMENT & APPROVALS
17.7 EXPANSIONS
17.8 REGULATORY CHANGES
17.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
18 GLOBAL ALZHEIMER’S DISEASE TREATMENT MARKET, COMPANY PROFILE
18.1 EISAI INC
18.1.1 COMPANY OVERVIEW
18.1.2 REVENUE ANALYSIS
18.1.3 GEOGRAPHIC PRESENCE
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 AUROBINDO PHARMACEUTICALS
18.3 CADILA HEALTHCARE
18.3.1 COMPANY OVERVIEW
18.3.2 REVENUE ANALYSIS
18.3.3 GEOGRAPHIC PRESENCE
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 DR REDDY LABORATORIES
18.4.1 COMPANY OVERVIEW
18.4.2 REVENUE ANALYSIS
18.4.3 GEOGRAPHIC PRESENCE
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 CIPLA, INC
18.5.1 COMPANY OVERVIEW
18.5.2 REVENUE ANALYSIS
18.5.3 GEOGRAPHIC PRESENCE
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENTS
18.6 LUPIN PHARMACEUTICALS
18.6.1 COMPANY OVERVIEW
18.6.2 REVENUE ANALYSIS
18.6.3 GEOGRAPHIC PRESENCE
18.6.4 PRODUCT PORTFOLIO
18.6.5 RECENT DEVELOPMENTS
18.7 SANDOZ INTERNATIONAL GMBH
18.7.1 COMPANY OVERVIEW
18.7.2 REVENUE ANALYSIS
18.7.3 GEOGRAPHIC PRESENCE
18.7.4 PRODUCT PORTFOLIO
18.7.5 RECENT DEVELOPMENTS
18.8 SUN PHARMACEUTICALS
18.8.1 COMPANY OVERVIEW
18.8.2 REVENUE ANALYSIS
18.8.3 GEOGRAPHIC PRESENCE
18.8.4 PRODUCT PORTFOLIO
18.8.5 RECENT DEVELOPMENTS
18.9 PRINSTON INC
18.9.1 COMPANY OVERVIEW
18.9.2 REVENUE ANALYSIS
18.9.3 GEOGRAPHIC PRESENCE
18.9.4 PRODUCT PORTFOLIO
18.9.5 RECENT DEVELOPMENTS
18.1 NOVARTIS
18.10.1 COMPANY OVERVIEW
18.10.2 REVENUE ANALYSIS
18.10.3 GEOGRAPHIC PRESENCE
18.10.4 PRODUCT PORTFOLIO
18.10.5 RECENT DEVELOPMENTS
18.11 AMNEAL PHARMACEUTICALS
18.11.1 COMPANY OVERVIEW
18.11.2 REVENUE ANALYSIS
18.11.3 GEOGRAPHIC PRESENCE
18.11.4 PRODUCT PORTFOLIO
18.11.5 RECENT DEVELOPMENTS
18.12 JOHNSON & JOHNOSN
18.12.1 COMPANY OVERVIEW
18.12.2 REVENUE ANALYSIS
18.12.3 GEOGRAPHIC PRESENCE
18.12.4 PRODUCT PORTFOLIO
18.12.5 RECENT DEVELOPMENTS
18.13 ABBVIE
18.13.1 COMPANY OVERVIEW
18.13.2 REVENUE ANALYSIS
18.13.3 GEOGRAPHIC PRESENCE
18.13.4 PRODUCT PORTFOLIO
18.13.5 RECENT DEVELOPMENTS
18.14 CELLTRION PHARMACEUTICALS
18.14.1 COMPANY OVERVIEW
18.14.2 REVENUE ANALYSIS
18.14.3 GEOGRAPHIC PRESENCE
18.14.4 PRODUCT PORTFOLIO
18.14.5 RECENT DEVELOPMENTS
18.15 HIKMA PHARMACEUTICALS
18.15.1 COMPANY OVERVIEW
18.15.2 REVENUE ANALYSIS
18.15.3 GEOGRAPHIC PRESENCE
18.15.4 PRODUCT PORTFOLIO
18.15.5 RECENT DEVELOPMENTS
18.16 ALEMBIC PHARMA LTD
18.16.1 COMPANY OVERVIEW
18.16.2 REVENUE ANALYSIS
18.16.3 GEOGRAPHIC PRESENCE
18.16.4 PRODUCT PORTFOLIO
18.16.5 RECENT DEVELOPMENTS
18.17 BIOGEN INC
18.17.1 COMPANY OVERVIEW
18.17.2 REVENUE ANALYSIS
18.17.3 GEOGRAPHIC PRESENCE
18.17.4 PRODUCT PORTFOLIO
18.17.5 RECENT DEVELOPMENTS
18.18 NOVARTIS AG
18.18.1 COMPANY OVERVIEW
18.18.2 REVENUE ANALYSIS
18.18.3 GEOGRAPHIC PRESENCE
18.18.4 PRODUCT PORTFOLIO
18.18.5 RECENT DEVELOPEMENTS
18.19 PFIZER INC.
18.19.1 COMPANY OVERVIEW
18.19.2 REVENUE ANALYSIS
18.19.3 GEOGRAPHIC PRESENCE
18.19.4 PRODUCT PORTFOLIO
18.19.5 RECENT DEVELOPEMENTS
18.2 ELI LILLY AND COMPANY
18.20.1 COMPANY OVERVIEW
18.20.2 REVENUE ANALYSIS
18.20.3 GEOGRAPHIC PRESENCE
18.20.4 PRODUCT PORTFOLIO
18.20.5 RECENT DEVELOPEMENTS
18.21 BRISTOL-MYERS SQUIBB COMPANY
18.21.1 COMPANY OVERVIEW
18.21.2 REVENUE ANALYSIS
18.21.3 GEOGRAPHIC PRESENCE
18.21.4 PRODUCT PORTFOLIO
18.21.5 RECENT DEVELOPMENTS
18.22 F. HOFFMANN LA ROCHE
18.22.1 COMPANY OVERVIEW
18.22.2 REVENUE ANALYSIS
18.22.3 GEOGRAPHIC PRESENCE
18.22.4 PRODUCT PORTFOLIO
18.22.5 RECENT DEVELOPMENTS
18.23 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
18.23.1 COMPANY OVERVIEW
18.23.2 REVENUE ANALYSIS
18.23.3 GEOGRAPHIC PRESENCE
18.23.4 PRODUCT PORTFOLIO
18.23.5 RECENT DEVELOPMENTS
18.24 VIATRIS INC.
18.24.1 COMPANY OVERVIEW
18.24.2 REVENUE ANALYSIS
18.24.3 GEOGRAPHIC PRESENCE
18.24.4 PRODUCT PORTFOLIO
18.24.5 RECENT DEVELOPMENTS
18.25 OTSUKA HOLDINGS
18.25.1 COMPANY OVERVIEW
18.25.2 REVENUE ANALYSIS
18.25.3 GEOGRAPHIC PRESENCE
18.25.4 PRODUCT PORTFOLIO
18.25.5 RECENT DEVELOPEMENTS
18.26 GLAXOSMITHKLINE
18.26.1 COMPANY OVERVIEW
18.26.2 REVENUE ANALYSIS
18.26.3 GEOGRAPHIC PRESENCE
18.26.4 PRODUCT PORTFOLIO
18.26.5 RECENT DEVELOPMENTS
18.27 UCB
18.27.1 COMPANY OVERVIEW
18.27.2 REVENUE ANALYSIS
18.27.3 GEOGRAPHIC PRESENCE
18.27.4 PRODUCT PORTFOLIO
18.27.5 RECENT DEVELOPEMNTS
18.28 AGENEBIO
18.28.1 COMPANY OVERVIEW
18.28.2 REVENUE ANALYSIS
18.28.3 GEOGRAPHIC PRESENCE
18.28.4 PRODUCT PORTFOLIO
18.28.5 RECENT DEVELOPEMNTS
18.29 QUINCE ETHERAPEUTICS
18.29.1 COMPANY OVERVIEW
18.29.2 REVENUE ANALYSIS
18.29.3 GEOGRAPHIC PRESENCE
18.29.4 PRODUCT PORTFOLIO
18.29.5 RECENT DEVELOPEMNTS
18.3 AVANIR PHARMACEUTICALS
18.30.1 COMPANY OVERVIEW
18.30.2 REVENUE ANALYSIS
18.30.3 GEOGRAPHIC PRESENCE
18.30.4 PRODUCT PORTFOLIO
18.30.5 RECENT DEVELOPEMNTS
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
19 RELATED REPORTS
20 CONCLUSION
21 QUESTIONNAIRE
22 ABOUT DATA BRIDGE MARKET RESEARCH
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
